Disease · MONDO_0044937
Trials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 12 of 12
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00682786 | Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma | Phase 2 | 135 | 2014-09-08 | Rectal Carcinoma | FLUOROURACIL, IRINOTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT02010567 | Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer | Phase 1/2 | 32 | 2017-11-14 | Rectal Cancer | CAPECITABINE, DAVAMOTECAN PEGADEXAMER | Its record names the disease | ClinicalTrials.gov |
| NCT01609231 | A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) | Phase 2 | 11 | 2020-05-04 | Rectal Neoplasms | DALOTUZUMAB, IRINOTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT02017704 | Chemoradiation or Brachytherapy for Rectal Cancer | Phase 2 | 9 | 2023-02-24 | Rectal Cancer | CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00309517 | Randomized Study on Neoadjuvant Radio-Chemotherapy in Rectal Carcinoma Dukes B and C | Phase 3 | 700 | Rectal Cancer Dukes B, Dukes C | EDRECOLOMAB, FLUOROURACIL, LEUCOVORIN CALCIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT01333709 | Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma | Phase 2 | 150 | Locally Advanced Malignant Neoplasm, Rectal Carcinoma | CAPECITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00297141 | Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma | Phase 2 | 60 | Rectal Cancer | CAPECITABINE, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02000050 | Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE) | Phase 2 | 52 | Rectal Carcinoma | FLUOROURACIL, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01434147 | Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy | Phase 2 | 25 | Rectal Cancer | BEVACIZUMAB, CAPECITABINE, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01372007 | Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma | Phase 3 | 24 | Rectal Carcinoma | LANREOTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00671645 | Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy | Phase 2 | 8 | Rectal Cancer | BEVACIZUMAB, CAPECITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02473094 | Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer | Phase 2 | 3 | Rectal Neoplasms, Adenocarcinoma, Carcinoma | CAPECITABINE, METFORMIN | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0044937/trials